key articles
A novel approach to the treatment of benign prostatic hyperplasia
The combined (alpha) (1)- and postsynaptically selective (alpha)(2)-blocker GYKI-16084 significantly improved the AUA symptom scores
BJU International Vol. 97
Three months' treatment with the (alpha)(1)-blocker alfuzosin does not affect total or transition zone volume of the prostate
Treatment with (alpha)(1)-adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia
Prostate Cancer and Prostatic Diseases Vol. 9
Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study
Starting administration at 75 mg/day rather than 25mg/day is helpful for LUTS associated with BPH for patients with moderate symptoms, particularly in improving voiding symptoms
International Journal of Urology Vol.13
Urtica dioica for treatment of benign prostatic hyperplasia a prospective, randomized, double-blind, placebo-controlled, crossover study
In the present study, Urtica dioica have beneficial effects in the treatment of symptomatic BPH
Journal of Herbal Pharmacotherapy Vol. 5
The Effects of Tamsulosin and Sildenafil in Separate and Combined Regimens on Detailed Hemodynamics in Patients With Benign Prostatic Enlargement
Tamsulosin does not disturb hemodynamics in patients with benign prostatic enlargement
Journal of Urology Vol. 176
Randomized trial comparing holmium laser enucleation of prostate with plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia
Plasmakinetic enucleation of the prostate is a safe and technically feasible procedure for the enucleation of prostatic adenomata
Urology Vol. 68
Efficacy and tolerability of the dual 5(alpha)-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men
The efficacy and tolerability of dutasteride (0.5mg daily for 2 years) in African-Americans (n=161), compared with Caucasians (n=3961), was assessed in a post hoc analysis of data from three Phase III clinical trials
Prostate Cancer and Prostatic Diseases Vol. 9
